loading

Finanzdaten der Enliven Therapeutics Inc-Aktie (ELVN)

Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31
Periodenlänge 3 Monate 3 Monate 3 Monate 3 Monate 3 Monate
Revenues
-
- - - -
Operating Expenses
14.33%
25.99
22.73 24.25 20.13 16.42
Operating Income/Loss
14.33%
-25.99
-22.73 -24.25 -20.13 -16.42
Nonoperating Income/Loss
3.27%
3.249
3.359 3.479 3.413 1.694
Income/Loss From Continuing Operations Before Tax
17.39%
-22.74
-19.37 -20.77 -16.72 -14.72
Income/Loss From Continuing Operations After Tax
17.39%
-22.74
-19.37 -20.77 -16.72 -14.72
Net Income/Loss
17.39%
-22.74
-19.37 -20.77 -16.72 -14.72
Preferred Stock Dividends And Other Adjustments
-
- - - -
Attributable To Noncontrolling Interest
-
- - - -
Basic Average Shares
2,135%
42.05
1.8811 41.03 40.96 18.51
Diluted Average Shares
2,135%
42.05
1.8811 41.03 40.96 18.51
Basic Earnings Per Share
17.39%
-0.54
-0.46 -0.51 -0.41 -0.80
Diluted Earnings Per Share
17.39%
-0.54
-0.46 -0.51 -0.41 -0.80
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic
-
- - - -
$72.36
price down icon 1.39%
$39.11
price up icon 8.69%
$373.11
price up icon 1.50%
$23.09
price up icon 4.62%
biotechnology ONC
$215.13
price down icon 1.63%
$115.49
price down icon 1.75%
Kapitalisierung:     |  Volumen (24h):